Morgan Stanley Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $755.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price decreased by Morgan Stanley from $958.00 to $755.00 in a research note published on Monday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock. A number of other analysts have also recently weighed in on REGN. BMO Capital Markets decreased […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price decreased by Morgan Stanley from $958.00 to $755.00 in a research note published on Monday morning,Benzinga reports. Morgan Stanley currently has an overweight rating on the biopharmaceutical company’s stock. A number of other analysts have also recently weighed in on REGN. BMO Capital Markets decreased […]
